Eculizumab in kidney diseases

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Fatemeh Pour- (Autor), Sara Assadiasl (Autor)
Formato: Livro
Publicado em: Society of Diabetic Nephropathy Prevention, 2024-01-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Número de Chamada: A1234.567
Cópia 1 Disponível